Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Dunad Therapeutics, a UK-based developer of protein degradation technology, launched yesterday with £5m ($7m) in funding from venture firm Epidarex Capital. Dunad advances research by co-founder, acting chief executive and chief scientific officer Prof Patrick Gunning, a researcher in University of Toronto Mississauga’s Department of Chemical and Physical Sciences.
Inotec AMD, a UK-based wound healing technology spinout of University of Cambridge, has pocketed £3.4m ($4.7m) in series C funding from Wealth Club. The spinout previously secured $9.1m in…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
